In this investigation, we examined the effects of genetic editing of the CCK-BR in murine PSC and also pharmacologic blockade of the CCK-BR in human PSC to understand the mechanisms of how interruption of the CCK-BR signaling pathway in PSC may decrease the aggressive nature of pancreatic cancer. The gene discussed is CCKBR; the disease is pancreatic neoplasm.